Edition:
United States

Puma Biotechnology Inc (PBYI.OQ)

PBYI.OQ on NASDAQ Stock Exchange Global Select Market

66.15USD
22 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$66.15
Open
--
Day's High
--
Day's Low
--
Volume
200
Avg. Vol
262,700
52-wk High
$136.90
52-wk Low
$28.35

Chart for

About

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous))... (more)

Overall

Beta: 0.24
Market Cap(Mil.): $2,482.58
Shares Outstanding(Mil.): 37.53
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 192.73 16.31
EPS (TTM): -- -- --
ROI: -- -0.67 35.74
ROE: -- -3.38 17.71

BRIEF-EMA Recommends Against Approval Of Puma Biotechnology's Breast Cancer Drug Neratinib‍​

* EU MEDICINES AGENCY RECOMMENDATIONS FOR FEBRUARY 2018 BREAST CANCER DRUG NERATINIB

7:15am EST

BRIEF-Puma Biotechnology And Canbridge Life Sciences Enter Into Exclusive Licensing Agreement To Commercialize Nerlynx In Greater China

* PUMA BIOTECHNOLOGY AND CANBRIDGE LIFE SCIENCES ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN GREATER CHINA Source text for Eikon: Further company coverage:

Feb 01 2018

BRIEF-Puma Biotechnology And Canbridge Life Sciences Enter Into Exclusive Licensing Agreement

* PUMA BIOTECHNOLOGY AND CANBRIDGE LIFE SCIENCES ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN GREATER CHINA

Feb 01 2018

BRIEF-Puma Biotechnology And Medison Pharma Enter Licensing Agreement To Commercialize Nerlynx In Israel

* PUMA BIOTECHNOLOGY AND MEDISON PHARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN ISRAEL

Jan 30 2018

Puma Biotechnology sinks after Europe unlikely to OK breast cancer drug

Puma Biotechnology Inc said on Tuesday a European regulatory panel indicated it was unlikely to provide a positive opinion on the company's breast cancer drug, sending its shares down 30 percent.

Jan 23 2018

Puma Biotechnology sinks after Europe unlikely to OK breast cancer drug

Jan 23 Puma Biotechnology Inc said on Tuesday a European regulatory panel indicated it was unlikely to provide a positive opinion on the company's breast cancer drug, sending its shares down 30 percent.

Jan 23 2018

BRIEF-Puma Biotechnology Intends To Modify Characteristics Summary In Neratinib Marketing Authorization Application

* PUMA BIOTECHNOLOGY INC SAYS IT MET WITH COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE SCIENTIFIC ADVISORY GROUP ON ONCOLOGY

Jan 11 2018

BRIEF-Daiichi Sankyo And Puma Biotechnology To Collaborate With Major Cancer Center In HER2-Mutated Cancer

* DAIICHI SANKYO AND PUMA BIOTECHNOLOGY ANNOUNCE RESEARCH COLLABORATION WITH MAJOR CANCER CENTER IN HER2-MUTATED CANCER Source text for Eikon: Further company coverage:

Dec 12 2017

BRIEF-Puma Biotechnology Announces Positive Outcome Of European Opposition Proceedings

* PUMA BIOTECHNOLOGY ANNOUNCES POSITIVE OUTCOME OF EUROPEAN OPPOSITION PROCEEDINGS

Dec 11 2017

BRIEF-PUMA BIOTECHNOLOGY, SPECIALISED THERAPEUTICS ASIA AGREE TO COMMERCIALIZE NERLYNX IN SOUTH EAST ASIA

* PUMA BIOTECHNOLOGY AND SPECIALISED THERAPEUTICS ASIA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN AUSTRALIA, NEW ZEALAND AND SOUTH EAST ASIA

Nov 22 2017

Earnings vs. Estimates